Lactose India Set for Shareholder Vote on Vitanosh Ingredients Merger

Vitanosh Ingredients reported revenue of ₹60.76 crore and a net loss of ₹3.66 crore for the half-year ended September 30, 2025.

Reader Takeaway: Vitanosh's losses persist despite revenue; merger aims for synergy gains.

What just happened

Lactose India Limited is calling an Extra Ordinary General Meeting (EGM) on March 28, 2026, to seek shareholder approval for its amalgamation with Vitanosh Ingredients Private Limited.

The proposed scheme involves a share exchange ratio where Vitanosh shareholders will receive 0.7946 equity shares of Lactose India for every one equity share they hold.

Key dates have been set for e-voting from March 25 to March 27, 2026, with book closure scheduled from March 22 to March 28, 2026.

Why this matters

This amalgamation aims to create a consolidated entity with enhanced manufacturing capabilities, broader market access, and potential cost efficiencies through operational synergies.

The combined business is expected to leverage these strengths to drive growth and improve profit margins.

The backstory

Lactose India Limited is a well-established manufacturer of pharmaceutical-grade lactose and lactulose, with facilities in Vadodara, Gujarat. Vitanosh Ingredients, incorporated in 2019, operates in the dairy products and milk processing sector.

The merger has already seen key procedural approvals, including a no-objection from the BSE on August 22, 2025, and a clearance of the first motion by the NCLT Ahmedabad on February 13, 2026.

What changes now

Upon successful amalgamation, Vitanosh Ingredients will merge into Lactose India Limited, creating a larger entity.

Shareholders of Vitanosh Ingredients will become shareholders of Lactose India, subject to the approved exchange ratio.

The combined entity will aim to integrate operations and capitalise on cross-sector opportunities between pharmaceutical ingredients and dairy processing.

Risks to watch

Lactose India's operations are susceptible to raw material price fluctuations, intense competition, and regulatory risks.

The combined entity may also face general risks from economic slowdown, recession, health pandemics, and natural calamities, as highlighted in the filing.

Operations are also considered working capital intensive.

Peer comparison

Lactose India operates in the pharmaceutical ingredients space, while Vitanosh is in dairy products. Key listed players in the Indian dairy sector include Hatsun Agro Product Ltd., Dodla Dairy Ltd., and Parag Milk Foods Ltd., which compete in a growing but fragmented market.

Context metrics (time-bound)

• Vitanosh Ingredients reported total income of ₹6,075.69 lakh (₹60.76 cr) for the half-year ended September 30, 2025.
• The company incurred a net loss of ₹365.73 lakh (₹3.66 cr) during the same period.
• For the year ended March 31, 2025, Vitanosh Ingredients had a total income of ₹11,839.93 lakh (₹118.40 cr) and a net loss of ₹4,750 lakh (₹47.50 cr).

What to track next

Shareholders of Lactose India Limited must approve the amalgamation scheme at the upcoming EGM.

Subsequent regulatory and statutory approvals will be crucial for the completion of the merger process.

Investors will monitor the financial performance of the combined entity post-amalgamation, focusing on synergy realisation and Vitanosh's profitability integration.